<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03775629</url>
  </required_header>
  <id_info>
    <org_study_id>CG100650-1-01</org_study_id>
    <nct_id>NCT03775629</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study of &quot;CG100650&quot; in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Multiple-dose, Parallel Study to Compare the Pharmacokinetics and to Evaluate Drug-Drug Interaction of &quot;CG100650&quot; in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CrystalGenomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CrystalGenomics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multiple-dose, parallel, Phase 1 study to compare the&#xD;
      pharmacokinetics and to evaluate Drug-Drug Interaction of &quot;CG100650&quot; in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open label, multiple-dose, parallel study to compare PK and to evaluate&#xD;
      Drug-Drug Interaction of CG100650 in healthy volunteers.&#xD;
&#xD;
      Total of 39 health volunteers will be randomized to receive either of Group A, B or C for 14&#xD;
      days (13 subjects each).&#xD;
&#xD;
      [Group A] 13 subjects will receive Tramadol HCl 300mg(150mg tablet *2) once/day (Administrate&#xD;
      from D10 to 14) + 2 mg Polmacoxib capsule once/day for 14 days(2 mg Polmacoxib capsule from&#xD;
      Day 3 ~ 14. But, 6 mg on DAY 1, 8 mg on Day 2) [Group B] Polmacoxib capsule once/day for 14&#xD;
      days (2 mg Polmacoxib capsule from Day 3 ~ 14. But, 6 mg on DAY 1, 8 mg on Day 2) [Group C]&#xD;
      Tramadol HCl 300mg(150mg tablet *2) once /day for 5 days (Administrate from Day 1 to 5)&#xD;
&#xD;
      * [Treatment]&#xD;
&#xD;
        -  Group A: Tramadol hydrochloride (HCl) 300mg and polmacoxib 2mg combination regimen&#xD;
&#xD;
        -  Group B: Polmacoxib 2mg capsule&#xD;
&#xD;
        -  Group C: Tramadol hydrochloride (HCl) 300mg&#xD;
&#xD;
      Pharmacokinetic parameters will be evaluated as primary endpoint by changes from baseline;&#xD;
      Polmacoxib AUCmax, Cmax in either of whole blood and serum, tramadol HCl AUCmax, Cmax in&#xD;
      serum. t1/2,SS, CL/F in whole blood will be evaluated as secondary endpoint.&#xD;
&#xD;
      Safety evaluation will be carried out by conducting vital sign, laboratory test, ECG, and&#xD;
      collecting AE, CM by different Group. Prevalence (%), average (SD) will be addressed using&#xD;
      descriptive statistics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group A: Tramadol hydrochloride (HCl) 75mg tablet +Polmacoxib 2mg capsule combination regimen Group B: Polmacoxib 2mg capsule Group C: Tramadol hydrochloride (HCl) 75mg tablet</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCtau of Polmacoxib in plasma</measure>
    <time_frame>1Day, 3Day 6 Day, 10Day, 13 Day, 14Day pre dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour after administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Polmacoxib in plasma</measure>
    <time_frame>1Day, 3Day 6 Day, 10Day, 13 Day, 14Day pre dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour after administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau of Tramadol in plasma</measure>
    <time_frame>1Day, 3 Day 4 Day, 5Day pre dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour after administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Tramadol in plasma</measure>
    <time_frame>1Day, 3 Day 4 Day, 5Day pre dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour after administration.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of Polmacoxib in Wole blood</measure>
    <time_frame>1Day, 3Day 6 Day, 10Day, 13 Day, 14Day pre dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour after administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC tau of Polmacoxib in Wole blood</measure>
    <time_frame>1Day, 3Day 6 Day, 10Day, 13 Day, 14Day pre dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour after administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax ss</measure>
    <time_frame>1Day, 3 Day 4 Day, 5Day pre dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour after administration or 1Day, 3Day 6 Day, 10Day, 13D Day, 14Day pre dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour after administration.</time_frame>
    <description>Polmacoxib in plasma and whole blood and Tramadol in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>1Day, 3 Day 4 Day, 5Day pre dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour after administration or 1Day, 3Day 6 Day, 10Day, 13D Day, 14Day pre dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour after administration.</time_frame>
    <description>Polmacoxib in plasma and whole blood and Tramadol in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>1Day, 3 Day 4 Day, 5Day pre dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour after administration or 1Day, 3Day 6 Day, 10Day, 13D Day, 14Day pre dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour after administration.</time_frame>
    <description>Polmacoxib in plasma and whole blood and Tramadol in plasma</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Polmacoxib and Tramadol combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tramadol HCl 300mg once/day + 2 mg Polmacoxib capsule once/day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polmacoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polmacoxib 2mg 14days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tramadol hydrochloride (HCl) 150mg 5days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polmacoxib and Tramadol combination</intervention_name>
    <description>Tramadol hydrochloride (HCl) 150mg, Polmacoxib 2mg</description>
    <arm_group_label>Polmacoxib and Tramadol combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polmacoxib</intervention_name>
    <description>Polmacoxib 2mg</description>
    <arm_group_label>Polmacoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol hydrochloride</intervention_name>
    <description>Tramadol hydrochloride (HCl) 150mg</description>
    <arm_group_label>Tramadol</arm_group_label>
    <other_name>Tramadol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged ≥ 19 years and ≤ 50 years&#xD;
&#xD;
          2. Without inborn or chronic disease and no symptoms in physical examination&#xD;
&#xD;
          3. BMI(Body Mass Index) result ≥ 18kg/m 2 and ≤ 30kg/m2&#xD;
&#xD;
          4. Adequate clinical laboratory test results as evidenced by Hematology, Hemostasis,&#xD;
             Biochemistry, Urinalysis, Serology and so on&#xD;
&#xD;
          5. After taking a rest in sitting position for 5 minutes, subjects who have blood&#xD;
             pressure (90 mmHg ≤ Systolic BP ≤ 139 mmHg, and 60 mmHg ≤ Diastolic BP ≤ 89 mmHg)&#xD;
&#xD;
          6. Subject who understand the objective, method of the study and the characteristics of&#xD;
             investigational drug and expected adverse events and provide written informed consent&#xD;
             prior to study participation&#xD;
&#xD;
          7. Negative pregnancy test(hCG) and agree to contraception during the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity to investigational products&#xD;
&#xD;
          2. History of hypersensitivity or allergic reaction to sulfonamide.&#xD;
&#xD;
          3. Patients with a history of asthma, acute rhinitis, nonspecific polyps, angioedema,&#xD;
             urticaria or allergic reactions to aspirin or other nonsteroidal anti- inflammatory&#xD;
             analgesics (including COX-2 inhibitors)&#xD;
&#xD;
          4. Genetically galactose intolerance, lactose intolerance or Glucose-Galactose&#xD;
             Malabsorption&#xD;
&#xD;
          5. Uncontrolled hypertension (over the Systolic BP 140 mm Hg or Diastolic BP 90 mmHG)&#xD;
&#xD;
          6. Edema or Fluid retention&#xD;
&#xD;
          7. AST / ALT &gt; 1.5 times the normal range including additional and Screening blood tests&#xD;
             before randomization.&#xD;
&#xD;
          8. MDRD &lt; 60mL / min / 1.73m2 including additional and Screening blood tests before&#xD;
             randomization.&#xD;
&#xD;
          9. Any of the ECG result as below at Screening visit:&#xD;
&#xD;
               -  PR interval &gt; 210 msec&#xD;
&#xD;
               -  QRS complex &gt; 120 msec&#xD;
&#xD;
               -  QTcF &gt; 450 msec&#xD;
&#xD;
         10. Patient with an active peptic ulcer or gastrointestinal bleeding&#xD;
&#xD;
         11. Patient with inflammatory intestinal disease such as Crohn's disease or ulcerative&#xD;
             colitis&#xD;
&#xD;
         12. Patient with Congestive Heart Failure (NYHA II - IV)&#xD;
&#xD;
         13. Established ischemic heart disease patients, peripheral arterial diseases, and/or&#xD;
             brain vascular diseases patient&#xD;
&#xD;
         14. patient with gastrointestinal related disease or gastrotomy history (except&#xD;
             appendicitis or hernia surgery) that may affect the absorption of the investigational&#xD;
             drug.&#xD;
&#xD;
         15. Patient participated in any other clinical trials or Bio-equivalence studies within 90&#xD;
             days prior to the first administration of the investigational drug.&#xD;
&#xD;
         16. Patient donated whole blood within 60 days, donated blood component within 14 days, or&#xD;
             received blood transfusion within 30 days prior to the first administration of the&#xD;
             investigational drug.&#xD;
&#xD;
         17. Taken medications like barbital or herbal medicines within 30 days or taken Over The&#xD;
             Counter medicines within 7 days prior to the first administration of the&#xD;
             investigational drug that may affect the clinical trial&#xD;
&#xD;
         18. Over smokers (tobacco &gt; 20 cigarettes/ days) within 30 days prior to Screening visit&#xD;
             or patient cannot quit smoking during and until the end of the clinical trial after&#xD;
             signed the Informed Consent Form to participate the clinical trial.&#xD;
&#xD;
         19. Excessive Alcohol consumer 30 days prior to Screening visit (more than 24 glasses&#xD;
             /week (1 glass =wine 150 ml, beer 360 ml, spirits 45 ml)) or cannot quit drinking&#xD;
             alcohol during and until the end of the clinical trial after signed the Informed&#xD;
             Consent Form to participate the clinical trial.&#xD;
&#xD;
         20. Excessive caffeine consumer (&gt; 5 drinks/ day)&#xD;
&#xD;
         21. Patient cannot accept medically acceptable contraception during and until the clinical&#xD;
             trial.&#xD;
&#xD;
         22. Any other reasons or situations that the investigator decides the patient is not&#xD;
             eligible to participate the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sangsook Cho, Ph.D.</last_name>
    <phone>+82 31 628 2873</phone>
    <email>scho@cgxinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chohee Park</last_name>
    <phone>+82 31 628 2872</phone>
    <email>chpark@cgxinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung-sang Yu, Ph.D</last_name>
    </contact>
    <contact_backup>
      <last_name>Sunwoo Jung, MD</last_name>
      <phone>+82-2-2072-4083</phone>
      <email>swj4991@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 9, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2018</study_first_posted>
  <last_update_submitted>December 11, 2018</last_update_submitted>
  <last_update_submitted_qc>December 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

